GSK Targets £40B Sales as Oncology Push and £1.9B Savings Plan Take Shape
Wed, September 23, 2026 at 1:02 PM GMT+3 6 min read
Key Points
-
Interested in GSK PLC Sponsored ADR? Here are five stocks we like better.
-
GSK is targeting more than £40 billion in sales, above the £36.4 billion consensus estimate, with oncology assets—including antibody-drug conjugates, BLENREP and Jemperli—driving much of the potential upside.
-
The company's simplification program is expected to generate £1.9 billion in savings, mostly to fund pipeline investment and support margins through upcoming HIV patent expirations; GSK expects margins to remain stable or improve from 2028 to 2030.
-
Key growth opportunities include the launches of Excentia, BLENREP, bepirovirsen and Nuvalent-derived medicines, while TRELEGY pricing pressure under the Inflation Reduction Act and tougher SHINGRIX comparisons are expected to weigh on 2027 performance.
-
MarketBeat Week in Review – 06/08 - 06/12
GSK (NYSE:GSK) Chief Financial Officer Julie Brown outlined the company's growth strategy, launch priorities and cost-savings plans during a discussion with Bank of America analyst Sachin Jain following the company's recent capital markets day.
Brown said GSK's strategic portfolio review identified seven major assets across roughly 18 indications for accelerated development, with particular emphasis on oncology. The company also announced a simplification program designed to generate £1.9 billion in savings, with most of the savings intended to fund pipeline investment.
→ NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
-
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion
Part of the savings is expected to support margins during the period when GSK faces patent expirations for dolutegravir-based HIV medicines. Brown said the company expects margins to be stable to improving from 2028 through 2030, despite the anticipated impact from patent losses. She said GSK has established a track record of investing in research and development while improving productivity, citing expected sales growth above 7%, profit growth above 11% and a margin improvement of more than 500 basis points over the 2021-to-2026 period.
Oncology a Key Difference in Revenue Expectations
Brown said the largest difference between GSK's outlook of more than £40 billion in sales and consensus estimates of £36.4 billion is in oncology. She cited the company's antibody-drug conjugate portfolio, including assets referred to as MORES and RISRES, as well as BLENREP and Jemperli.
→ These 3 Stocks Under $20 Have Wall Street Looking Past the Share Price
-
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat
She noted that GSK's forecasts include probability-of-technical-and-regulatory-success adjustments. Brown also said consensus may be slower to recognize newer products, including HIV innovations and Excentia.
GSK expects specialty medicines to provide a natural lift to profitability as the business mix evolves. Specialty products accounted for just over 40% of the business, compared with roughly one-third when Brown joined in early 2023, and are expected to exceed 50% by 2031, she said. The company is seeking to reduce selling, general and administrative expenses through productivity efforts while increasing R&D investment.
Launch Dynamics for Excentia and BLENREP
→ The AI Bottleneck Is Not Chips Anymore and 3 Pipeline Stocks Are Cashing In
Brown said Excentia, a twice-yearly biologic treatment for severe asthma, has faced a reimbursement and administrative hurdle in the United States because of its upfront cost under the "buy-and-bill" system. The product received a J-code on July 1, but Brown said the related administrative process only began to flow through insurer systems in recent weeks.
"We would expect, having removed one of the largest barriers," prescribing conditions to improve entering the fourth quarter, Brown said. GSK plans to provide an update on payer coverage and its patient access program with third-quarter results.
For BLENREP, Brown reiterated that GSK intends to "go slow to go big." She said the multiple myeloma treatment has strong clinical data, including a reduction in risk of death and improved progression-free survival, but requires careful monitoring of eye-related side effects. BLENREP is administered as a 30-minute infusion and could address an unmet need among community-treated patients, she said.
Outside the U.S., BLENREP has registrations in more than 50 countries and is generally used in the second-line setting, while its U.S. label is for third-line use. Brown said that difference means the U.S. patient population is generally older and frailer, requiring a different launch approach.
Hepatitis B and Nuvalent Launches
Brown described bepirovirsen as a potentially transformational opportunity in hepatitis B. She said the treatment produced a functional cure in 19% of patients and lowered surface antigen levels in additional patients. GSK has approval in Japan, where pricing negotiations are under way, and expects an approval decision in China around the middle of next year.
She identified China, the U.S. and Japan as the main commercial markets for the product. China has an estimated 75 million people affected by hepatitis B, she said, though GSK did not provide country-by-country sales timing or guidance.
Brown also highlighted launches from GSK's Nuvalent acquisition. She said idasanlimab had been approved ahead of its PDUFA date and that launch preparations were under way. Niltalisertib, a fourth-generation ALK therapy, has a PDUFA date toward the end of November for an initial second-line indication. GSK expects a potential first-line opportunity to emerge around 2029, with recruitment progressing well in ongoing trials.
Headwinds and Business Development Capacity
For 2027, Brown identified TRELEGY as GSK's principal headwind because of pricing implications associated with the Inflation Reduction Act. She said the effect has been incorporated into company forecasts but did not quantify it. She also cited tougher comparisons for products such as SHINGRIX, while noting that vaccination penetration outside the U.S. remains materially below U.S. levels.
Brown said GSK continues to evaluate external business-development opportunities alongside internal pipeline programs. Following the Nuvalent acquisition, the company's pro forma net debt-to-EBITDA ratio is just under two times, she said. GSK also expects to generate more than £10 billion in cash from operations this year. Brown said future deal decisions will be based on the quality of an asset rather than whether it is late-stage or early-stage.
About GSK (NYSE:GSK)
GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company researches, develops and manufactures medicines and vaccines for the prevention and treatment of disease, serving patients and healthcare providers in markets around the world.
GSK focuses on specialty medicines and vaccines in areas including infectious diseases, HIV, respiratory disease, immunology and oncology. Its products include prescription medicines, long-acting treatments and vaccines designed to protect against diseases such as shingles, meningitis, influenza and respiratory syncytial virus (RSV).
The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
The article "GSK Targets £40B Sales as Oncology Push and £1.9B Savings Plan Take Shape" was originally published by MarketBeat.
Yorumlar (0)
Giriş yaparak yorum yazabilirsin.
İlk yorumu sen yaz.